Celgene Corporation Announces Appointment of Jonathan Biller as Executive Vice President and General Counsel Following the Departure of Gerald F. Masoudi

Celgene Corporation (NASDAQ:CELG) today announced the appointment of
Jonathan Biller as Executive Vice President and General Counsel
effective July 3, 2018. Mr. Biller will be responsible for global legal
strategy and will serve on the company’s Executive Committee.

Mr. Biller will succeed Gerald F. Masoudi, Celgene’s Executive Vice
President and General Counsel since 2015. Mr. Masoudi is leaving Celgene
to return to Washington, D.C. with his family and assume the role of
Chief Legal Officer with a private company outside of the
biopharmaceutical industry.

“Jonathan has been an integral part of Celgene’s senior management team
for the last seven years. He has led our capital allocation strategy and
provided industry-wide leadership on U.S. corporate tax reform. His
extensive legal experience and deep understanding of Celgene enable him
to immediately strengthen our leadership team as General Counsel,” said
Mark J. Alles, Chairman and Chief Executive Officer of Celgene
Corporation. “Jerry has made many important contributions to Celgene,
and we wish him and his family all the best.”

Mr. Biller joined Celgene in 2011 and was most recently Senior Vice
President, Tax and Treasury and served as Celgene’s Treasurer. He joined
Celgene from Bunge Limited, a publicly traded agriculture and food
company, where he was General Counsel, Chief Tax Officer and Secretary
from 2008 to 2011. In this role, he managed a global legal team of more
than 100 professionals. Prior to Bunge, Mr. Biller held roles of
increasing responsibility at Alcon, Inc. He began his legal career at
Hopkins & Sutter before rising to the level of partner and served as a
partner at Foley & Lardner after the firms merged. Mr. Biller holds a
J.D. from Yale Law School and a B.A. from Brown University.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in the
discovery, development and commercialization of innovative therapies for
the treatment of cancer and inflammatory diseases through
next-generation solutions in protein homeostasis, immuno-oncology,
epigenetics, immunology and neuro-inflammation. For more information,
please visit www.celgene.com.
Follow Celgene on Social Media: @Celgene,
and YouTube.

Hyperlinks are provided as a convenience and for informational purposes
only. Celgene bears no responsibility for the security or content of
external websites.

Forward-Looking Statement

This press release contains forward-looking statements, which are
generally statements that are not historical facts. Forward-looking
statements can be identified by the words “expects,” “anticipates,”
“believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and
similar expressions. Forward-looking statements are based on
management’s current plans, estimates, assumptions and projections, and
speak only as of the date they are made. We undertake no obligation to
update any forward-looking statement in light of new information or
future events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which are
difficult to predict and are generally beyond our control. Actual
results or outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual Report
on Form 10-K and our other reports filed with the Securities and
Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180619006361/en/